Karsten Mahnke

Prof. Dr. Karsten Mahnke

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2007 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
KMKarsten Mahnke
Karsten Mahnke
KSKurt Schönfeld
Kurt Schönfeld
SFSabine Fondel
Sabine Fondel
SRSabine Ring
Sabine Ring
SKSvetlana Karakhanova
Svetlana Karakhanova
AEAlexander Herrmann Enk
Alexander Herrmann Enk
The aim of this study was to investigate whether depletion of CD4+CD25+ regulatory T cells (Treg) from melanoma patients affects immune responses against tumors. By application of recombinant IL‐2‐diphteria toxin fusion protein, also known as ONTAK, we were able to significantly reduce the frequency of Treg in peripheral blood, whereas other cell populations remained unaffected. The reduction of Treg started immediately after the first bolus of ONTAK with a dose of 5 μg ONTAK per kg bodyweight and lasted for 13 days with subsequent recovery thereafter. Successive ONTAK treatments further reduced the number of circulating Treg. Using the contact sensitizer DCP we show that all patients developed vast eczema after Treg depletion, whereas no or only mild eczematous reactions were detectable before ONTAK treatment. Corresponding induction of DCP‐specific CD4+ and CD8+ T cells were detectable. Moreover, after immunization of ONTAK treated patients with tumor antigen peptides, MelanA/MART‐1 and gp100, significant induction of peptide specific CD8+ T cells could be observed in 90% of the patients treated. These cells displayed effector functions, as they were able to lyse peptide‐pulsed target cells and secreted IFNγ upon restimulation. In aggregate, our data indicate that ONTAK depletes Treg in vivo significantly, resulting in enhanced immune functions and substantial development of antigen‐specific CD8+ T cells in vaccinated individuals.

1 August 2005 in Cancer Research
Verified
Journal Article
Closed access
KMKarsten Mahnke
Karsten Mahnke
YQYingjie Qian
Yingjie Qian
SFSabine Fondel
Sabine Fondel
JBJuergen Brueck
Juergen Brueck
CBChristian Becker
Christian Becker
AEAlexander H. Enk
Alexander H. Enk
Anti (α)-DEC-205 antibodies target to the DEC-205 receptor that mediates antigen presentation to T cells by dendritic cells. To exploit these properties for immunization purposes, we conjugated the melanoma antigen tyrosinase-related protein (TRP)-2 to αDEC-205 antibodies and immunized mice with these conjugates together with dendritic cell–activating oligonucleotides (CpG). Upon injection of the melanoma cell line B16, αDEC-TRP immunized mice were protected against tumor growth. Even more important for clinical applications, we were able to substantially slow the growth of implanted B16 cells by injection of αDEC-TRP2 conjugates into tumor bearing hosts. Approximately 70% of the animals were cured from existing tumors by treatment with αDEC conjugates carrying two different melanoma antigens (TRP-2 and gp100). This protection was due to induction of melanoma-specific CD4 and CD8 responses. Thus, these data show that targeting of dendritic cells in situ by the means of antibody-antigen conjugates may be a novel way to induce long-lasting antitumor immunity.

9 November 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
CSCinthia Silva-Vilches
Cinthia Silva-Vilches
SRSabine Ring
Sabine Ring
KMKarsten Mahnke
Karsten Mahnke
Adenosine (Ado) is a well-studied neurotransmitter, but it also exerts profound immune regulatory functions. Ado can (i) actively be released by various cells into the tissue environment and can (ii) be produced through the degradation of extracellular ATP by the concerted action of CD39 and CD73. In this sequence of events, the ectoenzyme CD39 degrades ATP into ADP and AMP, respectively, and CD73 catalyzes the last step leading to the production of Ado. Extracellular ATP acts as a “danger” signal and stimulates immune responses, i.e. by inflammasome activation. Its degradation product Ado on the other hand acts rather anti-inflammatory, as it down regulates functions of dendritic cells (DCs) and dampens T cell activation and cytokine secretion. Thus, the balance of proinflammatory ATP and anti-inflammatory Ado that is regulated by CD39+/CD73+ immune cells, is important for decision making on whether tolerance or immunity ensues. DCs express both ectoenzymes, enabling them to produce Ado from extracellular ATP by activity of CD73 and CD39 and thus allow dampening of the proinflammatory activity of adjacent leukocytes in the tissue. On the other hand, as most DCs express at least one out of four so far known Ado receptors (AdoR), DC derived Ado can also act back onto the DCs in an autocrine manner. This leads to suppression of DC functions that are normally involved in stimulating immune responses. Moreover, ATP and Ado production thereof acts as “find me” signal that guides cellular interactions of leukocytes during immune responses. In this review we will state the means by which Ado producing DCs are able to suppress immune responses and how extracellular Ado conditions DCs for their tolerizing properties.

26 July 2007 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
KMKarsten Mahnke
Karsten Mahnke
SRSabine Ring
Sabine Ring
TJTheron S. Johnson
Theron S. Johnson
SSSonja Schallenberg
Sonja Schallenberg
KSKurt Schönfeld
Kurt Schönfeld
AEAlexander H. Enk
Alexander H. Enk
Suppressive functions of CD4+CD25+ regulatory T cells (Treg) are mainly studied by their interaction with conventional T cells. However, there is evidence that Treg also interact with antigen‐presenting cells (APC), leading to suppression of APC function in in vitro coculture systems. Studying the in vivo distribution of Treg after injection, we found that Treg are located in direct proximity to dendritic cells (DC) and affect their functional maturation status. After contact to Treg, DC up‐regulate the inhibitory B7‐H3 molecule and display reduced numbers of MHC–peptide complexes, leading to impaired T cell stimulatory function. When Treg‐exposed DC were used to immunize animals against antigens, the DC failed to produce a robust immune response as compared to control DC. Thus, these data indicate that Treg are able to inhibit DC activation and produce an inhibitory phenotype of DC. Accordingly, Treg may recruit DC for the amplification of immunosuppression by restraining their maturation in vivo and inducing an immunosuppressive phenotype of DC.

1 November 2007 in Cellular Immunology
Verified
Journal Article
Closed access
KMKarsten Mahnke
Karsten Mahnke
TBTanja Bedke
Tanja Bedke
AEAlexander H. Enk
Alexander H. Enk

1 December 2005 in Diabetes
Verified
Journal Article
Open access
PDF file
DBDunja Bruder
Dunja Bruder
AWAstrid M. Westendorf
Astrid M. Westendorf
WHWiebke Hansen
Wiebke Hansen
SPSilvia Prettin
Silvia Prettin
AGAchim D. Gruber
Achim D. Gruber
JBJan Buer
Jan Buer
Targeting of antigens to immature dendritic cells has been shown to result in antigen-specific T-cell tolerance in vivo. In the INS-HA/TCR-HA transgenic mouse model for type 1 diabetes, we tested the potential of the dendritic cell–specific monoclonal antibody DEC-205 conjugated to the hemagglutinin (HA) antigen (DEC-HA) to prevent disease onset. Whereas untreated INS-HA/TCR-HA mice all develop insulitis, and ∼40% of these mice become diabetic, repeated injection of newborn mice with DEC-HA protected almost all mice from disease development. Histological examination of the pancreata revealed significant reduction of peri-islet infiltrations in DEC-HA–treated mice, and the islet structure remained intact. Moreover, HA-specific CD4+ T-cells from anti–DEC-HA–treated INS-HA/TCR-HA mice exhibited increased expression of Foxp3, cytotoxic T-lymphocyte–associated antigen-4, and the immunosuppressive cytokines interleukin-10 and transforming growth factor-β. The findings indicate that targeting of the HA antigen to immature dendritic cells in vivo leads to a relative increase of antigen-specific Foxp3+ regulatory T-cells that suppress the development of type 1 diabetes. Our results provide a basis for the development of novel strategies focusing on prevention rather than treatment of autoimmune diseases.